GHRP-6 stimulation testing helped characterize ectopic ACTH syndrome from lung carcinoid by showing preserved GH response alongside ectopic ACTH production — using GH peptide testing for cancer endocrine diagnosis.
Key findingGHRP-6 stimulation in ACTH-dependent Cushing's from lung carcinoid showed preserved GH response with ectopic ACTH source characteristics, demonstratin
What the researchers found
GHRP-6 stimulation in ACTH-dependent Cushing's from lung carcinoid showed preserved GH response with ectopic ACTH source characteristics, demonstrating GH secretagogue testing utility for diagnosing ectopic versus pituitary ACTH production in Cushing's syndrome.
Why it matters
Relevant for ghrp, cancer, hormone-optimization.
How the study worked
case-report study on ghrp, cancer.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing's syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression.
Journal of endocrinological investigation, 30(4), 334-40
Citation
Machado, M C; Sá, S V; Goldbaum, T S; Catania, M; Campos, V C; Corrêa-Giannella, M L; Giannella-Neto, D; Salgado, L R. (2007). In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing's syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression.. Journal of endocrinological investigation, 30(4), 334-40.